Prostate Cancer clinical trials in West Virginia

2 actively recruiting prostate cancer trials at 1 site across West Virginia.

Data from ClinicalTrials.gov · last refreshed 2026-10-19

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Regeneron Pharmaceuticals funds and runs this clinical trial (NCT03972657). In 2024, Regeneron Pharmaceuticals reported paying the doctors leading the trial a total of $2,249,252 for research work on this study.

Who paid

Regeneron Pharmaceuticals, Inc. $2,249,252

Paid for research work on this trial

BILAL SIDDIQUI $843,045
EDWARD GELMANN(oncologist on CancerDrs) $282,711
BENEDITO CARNEIRO FILHO(oncologist on CancerDrs) $234,450
DAVID WISE(oncologist on CancerDrs) $232,180
CHE-KAI TSAO(oncologist on CancerDrs) $172,450

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT03678025

Sites in West Virginia:

West Virginia University Healthcare — Morgantown, West Virginia

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…

Sponsor: Regeneron Pharmaceuticals

NCT ID: NCT03972657

Sites in West Virginia:

West Virginia University — Morgantown, West Virginia

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19